We are live on ! Find out more
HRTX icon

Heron Therapeutics

193 hedge funds and large institutions have $1.1B invested in Heron Therapeutics in 2020 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 80 increasing their positions, 49 reducing their positions, and 42 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more repeat investments, than reductions

Existing positions increased: 80 | Existing positions reduced: 49

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

7% less first-time investments, than exits

New positions opened: 39 | Existing positions closed: 42

3% less funds holding

Funds holding: 199 → 193 (-6)

7.31% less ownership

Funds ownership: 109.99% → 102.69% (-7.3%)

39% less capital inflows, than outflows

Capital inflows: $219M | Capital outflows: $360M

39% less call options, than puts

Call options by funds: $5.87M | Put options by funds: $9.7M

Holders
193
Holders Change
-6
Holders Change %
-3.02%
% of All Funds
4.24%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
39
Increased
80
Reduced
49
Closed
42
Calls
$5.87​M
Puts
$9.7​M
Net Calls
-⁠$3.79​M
Net Calls Change
-⁠$3.92​M

HRTX Hedge Fund Activity: Q1 2020 in Review

193 of the 4,552 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q1 2020, worth a combined $1.1B — down 53% from $2.33B a quarter earlier.

Sellers outnumbered buyers: 42 funds closed out of HRTX and 39 opened new positions — a net loss of 3 holders — while 49 trimmed existing stakes and 80 added.

The largest buyer was PFM Health Sciences, opening a new position worth an estimated $46.7M. The largest seller was Fidelity Investments, cutting an estimated $76.4M.

  • 193 institutional investors held Heron Therapeutics (HRTX) as of Q1 2020, down from 199 in Q4 2019.
  • Funds reported $1.1B of Heron Therapeutics stock for Q1 2020, down 53% quarter-over-quarter.
  • 39 funds opened new Heron Therapeutics positions in Q1 2020 and 42 closed out, a net change of -3 holders.
  • The largest Heron Therapeutics buyer in Q1 2020 was PFM Health Sciences, an estimated $46.7M added.
  • The largest Heron Therapeutics seller in Q1 2020 was Fidelity Investments, an estimated $76.4M sold.

Based on aggregated 13F filings for Q1 2020.